Anti-inflammatory tripeptide (alpha-MSH fragment)
KPV
Research use only
Written by pep4U Editorial Team · Last reviewed October 12, 2026
A tiny peptide from alpha-MSH that keeps the parent hormone's anti-inflammatory action without causing pigmentation.
Go deeper. We have a full, in-depth research deep dive on this compound.
Read it → | Class / type | Anti-inflammatory tripeptide (alpha-MSH fragment) |
|---|
| Category | Healing, Recovery & Immune |
|---|
| Status (Jul 2026) | Research use only |
|---|
How it works
Binds melanocortin receptors (MC1R/MC3R) and enters cells via PepT1 to inhibit NF-kB, reducing TNF-alpha, IL-6 and other cytokines.
Known / used for
Gut inflammation / IBD models, gut-barrier support, skin inflammation, general anti-inflammatory use.
Positives
Targeted anti-inflammatory action in preclinical colitis; small, stable, orally absorbable; no pigmentation effect.
Negatives & risks
No completed human trials - evidence entirely preclinical; human safety/dosing not established; gray-market purity risk.
What people like most (reported community sentiment - not endorsement)
Gut-calming/digestive relief and reduced inflammation; oral-delivery convenience.
Frequently asked questions
What is KPV?
A tiny peptide from alpha-MSH that keeps the parent hormone's anti-inflammatory action without causing pigmentation. Binds melanocortin receptors (MC1R/MC3R) and enters cells via PepT1 to inhibit NF-kB, reducing TNF-alpha, IL-6 and other cytokines.
What is KPV used or researched for?
Gut inflammation / IBD models, gut-barrier support, skin inflammation, general anti-inflammatory use.
Is KPV FDA-approved or legal?
NOT FDA-approved. On Jul 23, 2026 the FDA's PCAC voted to recommend it for 503A compounding. The vote is advisory and non-binding, with no final rule issued yet. The next step is formal FDA rulemaking with a public comment period, and the FDA may allow interim enforcement discretion in the meantime. Verify.
What are the main risks or downsides of KPV?
No completed human trials - evidence entirely preclinical; human safety/dosing not established; gray-market purity risk.
Legal / regulatory status
NOT FDA-approved. On Jul 23, 2026 the FDA's PCAC voted to recommend it for 503A compounding. The vote is advisory and non-binding, with no final rule issued yet. The next step is formal FDA rulemaking with a public comment period, and the FDA may allow interim enforcement discretion in the meantime. Verify.
Recommended supplies
See all supplies →As an Amazon Associate we earn from qualifying purchases.
← Back to Healing, Recovery & Immune